WO2008045389A3 - An improved molecular diagnostic and computerized decision support system incorporating bioinformatic software for selecting the optimum treatment for human cancer - Google Patents

An improved molecular diagnostic and computerized decision support system incorporating bioinformatic software for selecting the optimum treatment for human cancer Download PDF

Info

Publication number
WO2008045389A3
WO2008045389A3 PCT/US2007/021500 US2007021500W WO2008045389A3 WO 2008045389 A3 WO2008045389 A3 WO 2008045389A3 US 2007021500 W US2007021500 W US 2007021500W WO 2008045389 A3 WO2008045389 A3 WO 2008045389A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
support system
decision support
cancer
selecting
Prior art date
Application number
PCT/US2007/021500
Other languages
French (fr)
Other versions
WO2008045389A2 (en
Inventor
Kung Ying Chiu
Original Assignee
Genetics Dev Corp
Kung Ying Chiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Dev Corp, Kung Ying Chiu filed Critical Genetics Dev Corp
Publication of WO2008045389A2 publication Critical patent/WO2008045389A2/en
Publication of WO2008045389A3 publication Critical patent/WO2008045389A3/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Bioethics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Artificial Intelligence (AREA)
  • Biomedical Technology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A computerized decision support system and method for predicting which of one or more drugs suitable to treat a cancerous condition in a patient are the optimum drug(s), where such selection is based upon the particular patient' s genotype. A PCR kit and/or a gene chip detects multiple genes, expressions and/or mutations associated with a particular cancer using a sample of the patient's tissue or blood. A detector accepts the gene chip and analyzes the patient's genotype; and a computerized system utilizing a gene expression cutoff point uses a database which associates patient genotypes and the efficacy and toxicity of various anti-cancer drugs used in treating patients with a particular cancerous condition connected to the detector to correlate the output of the detector to the database to provide a definitive recommendation as to which drug or drugs are optimum for treating the patient's cancer.
PCT/US2007/021500 2006-10-05 2007-10-05 An improved molecular diagnostic and computerized decision support system incorporating bioinformatic software for selecting the optimum treatment for human cancer WO2008045389A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85006606P 2006-10-05 2006-10-05
US60/850,066 2006-10-05

Publications (2)

Publication Number Publication Date
WO2008045389A2 WO2008045389A2 (en) 2008-04-17
WO2008045389A3 true WO2008045389A3 (en) 2008-11-06

Family

ID=39283403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021500 WO2008045389A2 (en) 2006-10-05 2007-10-05 An improved molecular diagnostic and computerized decision support system incorporating bioinformatic software for selecting the optimum treatment for human cancer

Country Status (1)

Country Link
WO (1) WO2008045389A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107145735A (en) * 2017-05-04 2017-09-08 中国药科大学 It is a kind of to assess the method that adverse reaction tendency occurs for medicine

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20105252A0 (en) 2010-03-12 2010-03-12 Medisapiens Oy METHOD, ORGANIZATION AND COMPUTER SOFTWARE PRODUCT FOR ANALYZING A BIOLOGICAL OR MEDICAL SAMPLE
CA2830550A1 (en) * 2011-03-18 2012-09-27 The Cleveland Clinic Foundation Clinical decision support system
CN112365951B (en) * 2020-11-24 2024-03-08 竹安（北京）生物科技发展有限公司 Tumor drug guiding system and method based on immunodetection
CN114334078B (en) * 2022-03-14 2022-06-14 至本医疗科技（上海）有限公司 Method, electronic device, and computer storage medium for recommending medication
CN115295116B (en) * 2022-08-04 2023-09-19 上海康黎医学检验所有限公司 Medicine comment method, system and electronic equipment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160114A1 (en) * 2004-12-02 2006-07-20 Oncotech, Inc. Reagents and methods for predicting drug resistance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160114A1 (en) * 2004-12-02 2006-07-20 Oncotech, Inc. Reagents and methods for predicting drug resistance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARDNER ET AL.: "New tools for cancer chemotherapy: computational assistance for tailoring treatments", MOLECULAR CANCER THERAPEUTICS, vol. 2, 2003, pages 1079 - 1084 *
JAIN: "Personalixed medicine for cancer: from drug development into clinical practice", EXPERT OPINION IN PHARMACOTHERAPY, vol. 6, no. 9, 2005, pages 1463 - 1476, XP009142630 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107145735A (en) * 2017-05-04 2017-09-08 中国药科大学 It is a kind of to assess the method that adverse reaction tendency occurs for medicine
CN107145735B (en) * 2017-05-04 2019-08-06 中国药科大学 A method of adverse reaction tendency occurs for assessment drug

Also Published As

Publication number Publication date
WO2008045389A2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2003017038A3 (en) A molecular diagnostic and computerized decision support system for selecting the optimum treatment for human cancer
WO2008045389A3 (en) An improved molecular diagnostic and computerized decision support system incorporating bioinformatic software for selecting the optimum treatment for human cancer
CN101892311B (en) Detection method and kit of single nucleotide polymorphism locus rs7550536 of susceptibility gene of hypertension
WO2003082078A3 (en) Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
WO2008027912A3 (en) Prediction of an agent's or agents' activity across different cells and tissue types
JIANG et al. Association of angiotensin Ⅱ type 1 receptor gene polymorphism with essential hypertension
WO2012116229A3 (en) Compositions and methods for personal tumor profiling treatment
Nakamoto et al. Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngeal muscular dystrophy
Tallerico et al. Dopamine D2 receptor promoter polymorphism: no association with schizophrenia
Hwang et al. Changes in DNA methylation after 6‐week exercise training in colorectal cancer survivors: A preliminary study
Smolińska et al. Genistein modulates gene activity in psoriatic patients
Lim et al. Prevalence of mupirocin resistance in methicillin-resistant Staphylococcus aureus strains isolated from a Malaysian hospital
Lurie Ayurveda and pharmacogenomics
CN101892296B (en) Method for detecting hypertension susceptible gene and detection kit
Sawadogo et al. Genetic mutations conferring resistance to candida albicans to antifungal drugs: a global perspective and regional implications
Pierola et al. Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones
CN109593853A (en) Primer sets, kit and the method for gene polymorphism sites detection
CN101892298A (en) Method for detecting mononucleotide polymorphism rs2236055 locus of hypertension susceptibility gene and kit thereof
Nand Yadav et al. EPCT-07. ID1 IS A KEY TRANSCRIPTIONAL REGULATOR OF DIPG INVASION AND IS TARGETABLE WITH CANNABIDIOL
Fang et al. MedPulse
WO2005042762A3 (en) Lrpap1 genetic markers associated with galantamine response
Machado et al. [PP. 30.30] STANDARDIZATION OF THE SNAPSHOT™ MULTIPLEX SYSTEM FOR ANALYSES OF GENETIC POLYMORPHISMS ASSOCIATED WITH HYPERTENSION AND OBESITY IN STUDENTS 10–15 YO. RIO DE JANEIRO STUDY II
Adams Development of a self-report screening instrument for assessing risk of opioid medication misuse in chronic pain patients.
Herasymenko Personalized oncology as a global uniting aim of clinical experience, unified protocols and modern technologies on the way to the victory against neoplastic processes
Kavaliauskaite et al. Studies of MIR-7, MIR-10B, MIR-30B and MIR-181A expression in different grades of glioma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839351

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07839351

Country of ref document: EP

Kind code of ref document: A2